Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients-Reference-Cited by-同舟云学术

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients

Published:2019-07-26 Issue:1 Volume:178 Page:57-62
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Del Re Marzia,Bertolini Ilaria,Crucitta Stefania,Fontanelli Lorenzo,Rofi Eleonora,De Angelis Claudia,Diodati Lucrezia,Cavallero Diletta,Gianfilippo Giulia,Salvadori Barbara,Fogli Stefano,Falcone Alfredo,Scatena Cristian,Naccarato Antonio Giuseppe,Roncella Manuela,Ghilli Matteo,Morganti Riccardo,Fontana Andrea,Danesi Romano^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05365-y.pdf

Reference22 articles.

1. Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ (2016) High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22:5514–5526. https://doi.org/10.1158/1078-0432.CCR-15-1984

2. Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumuller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX (2017) Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res 19:123. https://doi.org/10.1186/s13058-017-0913-7

3. Berghuis AM, Koffijberg H, Prakash J, Terstappen LW, IJzerman M (2017) Detecting blood-based biomarkers in metastatic breast cancer: a systematic review of their current status and clinical utility. Int J Mol Sci. https://doi.org/10.3390/ijms18020363

4. Bjohle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Soderberg M, Sundquist M, Walz TM, Ferno M, Bergh J, Hatschek T (2013) Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat 139:751–758. https://doi.org/10.1007/s10549-013-2579-x

5. Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW (2016) Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther 15:2273–2281. https://doi.org/10.1158/1535-7163.MCT-16-0300

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased levels of thymidine kinase 1 in malignant cell-derived extracellular vesicles;Biochemistry and Biophysics Reports;2024-09

2. Docking and Molecular Dynamics Studies on Anticancer Activities of Flavonoids as Inhibitors of CDK2 and CDK9;Medicinal Chemistry;2024-08-28

3. Extracellular vesicles for breast cancer diagnosis and therapy;Extracellular Vesicle;2024-06

4. Exosomal microRNAs in breast cancer: towards theranostic applications;Frontiers in Molecular Biosciences;2024-02-22

5. The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility;Critical Reviews in Oncology/Hematology;2023-12